By Fineline Cube 
China‑based Pharmaron Beijing Co., Ltd. (HKG: 3759) announced on October 28, 2025 that it will acquire an 82.54% stake in Biortus Biosciences Co., Ltd. for roughly RMB 1.346 billion (≈ US $200 million). The transaction will make Biortus a Pharmaron subsidiary and deepen the group’s footprint in contract research services that leverage structural biology expertise.
Strategic Rationale Behind the Deal
Biortus, a leading Chinese contract research organization (CRO), specializes in structural biology‑related R&D and boasts a strong Cryo‑Electron Microscopy (Cryo‑EM) platform. The acquisition is expected to enrich Pharmaron’s portfolio of cutting‑edge biopharmaceutical services, enabling the company to offer end‑to‑end solutions for drug discovery and development across biotech and pharma clients.
Financial and Operational Highlights
Biortus was incorporated in China with a registered capital of RMB 52,333,424. Its Cryo‑EM technology provides high‑resolution structural insights that are critical for drug target validation and affinity maturation. Following the deal, Pharmaron plans to integrate Biortus’s CRO team and infrastructure, creating synergies that could accelerate portfolio development and shorten time‑to‑market for partner drugs.
Market Impact and Outlook
The transaction underscores Pharmaron’s strategy to grow its CRO business in a rapidly expanding Chinese biotech ecosystem. Analysts note that the combined entity’s enhanced Cryo‑EM capabilities could position Pharmaron as a preferred external partner for global pharma firms seeking advanced structural biology services, potentially driving revenue growth in the coming fiscal years.-Fineline Info & Tech